Literature DB >> 27463208

Autologous Unpurged Bone Marrow Transplantation for Acute Non Lymphoblastic Leukemia in First Remission.

A M Carella1, S Nati1, P Carlier1, D Pierluigi1, D Giordano2, A Congiu2, G Santini2, D Scarpati3, S Barra4, R Corvo4, V Vitale4, M R Raffo2, R Cerri2, M Risso2, M Spriano2, R Vimercati2, E Pungolino2, A Bacigalupo1, E Damasio2.   

Abstract

Forty consecutive adult patients under the age of 50 with acute non-lymphoblastic leukemia (ANLL) in first complete remission, underwent autologous bone marrow transplantation (ABMT) between March 1984 and April 1990. The conditioning regimen employed included cyclophosphamide and total body irradiation, followed by the administration of unpurged ABMT. The median time from diagnosis to transplant was 7 months (3-15 months), and the median time from complete remission to ABMT was 4 months (range 3-9 months). Twenty-two (51%) patients remain in complete remission 6-81 months (median 24 months) after ABMT. The causes of death were, recurrent leukemia (11 patients), parenchymal toxicities such as acute respiratory distress syndrome and veno-occlusive disease (3 patients), hemorrhage (2 patients) and infection (2 patients). Eleven patients relapsed after 3-12 months (median 5 months). This study has produced survival data comparable to those of other institutions employing TBI for either allo or autotransplants.

Entities:  

Keywords:  ANLL; Autologous BMT

Year:  1991        PMID: 27463208     DOI: 10.3109/10428199109068103

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  1 in total

1.  Autologous and allogeneic bone marrow transplantation in acute myeloid leukemia in first complete remission: an update of the Genoa experience with 159 patients.

Authors:  A M Carella; F Frassoni; M T van Lint; F Gualandi; D Occhini; P Carlier; N Pollicardo; E Pungolino; F Fagioli; G Santini
Journal:  Ann Hematol       Date:  1992-03       Impact factor: 3.673

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.